Nine-month interim report (Q3) 2024 (unaudited) - English version only
14. November 2024 01:30 ET
|
ALK Abello
Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales...
Nine-month interim report (Q3) 2024 (unaudited)
14. November 2024 01:30 ET
|
ALK Abello
Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet...
ALK indlicenserer rettigheder til neffy®, den første godkendte næsespray med adrenalin til akut behandling af allergiske reaktioner (anafylaksi)
09. November 2024 17:30 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at selskabet har indgået en strategisk licensaftale med USA-baserede ARS Pharmaceuticals, Inc. (”ARS Pharma”) (NASDAQ: SPRY). Aftalen giver ALK...
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
09. November 2024 17:30 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK...
Invitation til præsentation af ALK’s regnskab for de første ni måneder (Q3) 2024 torsdag den 14. november 2024
07. November 2024 06:09 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for de første ni måneder (Q3) af 2024 om morgenen torsdag den 14. november 2024. ALK afholder senere samme dag kl. 13.30 (CET) en...
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
07. November 2024 06:09 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine months (Q3) 2024 in the morning of Thursday 14 November 2024. Later same day, the company will host a presentation for...
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
27. August 2024 11:30 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende...
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
27. August 2024 11:30 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
Six-month interim report (Q2) 2024 - English version only
22. August 2024 11:49 ET
|
ALK Abello
Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet...
Six-month interim report (Q2) 2024
22. August 2024 11:49 ET
|
ALK Abello
Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet...